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Abstract
The new superbug Neisseria gonorrhoeae has retained resistance to antimicrobials previously
recommended for first-line treatment and has now demonstrated its capacity to develop resistance
to the extended-spectrum cephalosporin, ceftriaxone, the last remaining option for first-line
empiric treatment of gonorrhea. An era of untreatable gonorrhea may be approaching, which
represents an exceedingly serious public health problem. Herein, we review the evolution, origin
and spread of antimicrobial resistance and resistance determinants (with a focus on extended-
spectrum cephalosporins) in N. gonorrhoeae, detail the current situation regarding verified
treatment failures with extended-spectrum cephalosporins and future treatment options, and
highlight essential actions to meet the large public health challenge that arises with the possible
emergence of untreatable gonorrhea. Essential actions include: implementing action/response
plans globally and nationally; enhancing surveillance of gonococcal antimicrobial resistance,
treatment failures and antimicrobial use/misuse; and improving prevention, early diagnosis and
treatment of gonorrhea. Novel treatment strategies, antimicrobials (or other compounds) and,
ideally, a vaccine must be developed.
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Public health concerns regarding gonorrhea & antimicrobial-resistant
Neisseria gonorrhoeae
The sexually transmitted infection gonorrhea (etiological agent Neisseria gonorrhoeae) is
associated with high morbidity and socioeconomic consequences, remaining a major public
health concern worldwide. In 2008, the WHO estimated 106 million new gonorrhea cases
among adults (a similar global incidence to genital chlamydial infections), which
represented a 21% increase since 2005 [201]. If gonorrhea remains undetected and/or
untreated, the additional morbidity may be severe and includes pelvic inflammatory disease,
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infertility, ectopic pregnancy, first trimester abortion, neonatal conjunctivitis leading to
blindness and, less commonly, male infertility and disseminated gonococcal infections.
Gonorrhea also enhances the transmission of HIV [1,2,202]. Control of gonorrhea relies on
prevention, appropriate diagnostics and effective antimicrobial treatment [1]. Antimicrobial
therapy should cure individual cases to reduce the risk of complications as well as end
further transmission of the infection, which is an important public health strategy to decrease
the gonorrhea burden in a population.
The first truly effective antigonococcal agent, penicillin G, was introduced in 1943 and was
effective for about 40 years (albeit by repeated increases in the dose) until widespread
resistance necessitated a change to other antimicrobials. Unfortunately, antimicrobial
resistance (AMR) has emerged for essentially all antimicrobials following their introduction
into clinical practice. Over the last 70–80 years, treatment options have diminished rapidly
due to the emergence and spread of AMR to all drugs previously used or considered for
first-line treatment (penicillins, tetracyclines, spectinomycin, narrow-spectrum
cephalosporins, amphenicols, sulfonamide and trimethoprim combinations, macrolides and
fluoroquinolones). Currently, the extended-spectrum cephalosporins (ESCs), ceftriaxone
(injectable) and cefixime (oral), are the only first-line options for the antimicrobial
monotherapy of gonorrhea in most settings globally; however, during the most recent
decade, global susceptibility to these antibiotics has markedly decreased [1,3–20] and
clinical treatment failures with these ESCs have been verified [21–30]. In particular, it is of
concern that during the last 2 years, the first three extensively drug-resistant (XDR; defined
in [1]) N. gonorrhoeae strains with high-level resistance to ceftriaxone, the last remaining
option for empiric single antimicrobial treatment, were reported from Japan [23], France
[25] and Spain [31]. The threat of widespread ceftriaxone resistance and untreatable
gonorrhea, particularly in settings where dual antimicrobial therapy is not feasible and/or
affordable, is real [1,4,17,23,25,32]. In response to this developing situation, the WHO has
published the ‘Global Action Plan to Control the Spread and Impact of Antimicrobial
Resistance in Neisseria gonorrhoeae’ [33,202]. The European CDC and the US CDC have
published region-specific response plans for the EU/European Economic Area (EU/EEA)
countries [203] and the USA, respectively [204].
Evolution, origin & spread of AMR in N. gonorrhoeae
Since the beginning of the antimicrobial era (1930s), N. gonorrhoeae has repeatedly
demonstrated its extraordinary capacity to develop resistance to all antimicrobials
introduced for treatment of gonorrhea. After introduction of a new antimicrobial, resistance
has emerged and been spread internationally after only 1–2 decades [17]. Gonococci utilize
most of the known mechanisms of AMR: drug inactivation, alteration of antimicrobial
targets, increased export and decreased uptake. Of particular concern are the mechanisms
that alter the permeability of the gonococcal cell that can affect a wide range of
antimicrobials with different modes of action, including penicillins, cephalosporins,
tetracyclines and macrolides. AMR mechanisms arise from specific chromosomal mutations,
conjugation of resistance plasmids and external gene transfer (transformation and
subsequent recombination of whole or parts of resistance genes), particularly from other
Neisseria species. Since N. gonorrhoeae is naturally competent for uptake and
recombination of external DNA during its entire life cycle, the transfer of chromosomally
encoded resistance genes is both rapid and extensive [1,11,17].
Exposure of Neisseria spp. to antimicrobials (for treatment of gonorrhea or other infections)
can result in the selection of resistant strains, due to spontaneous gene mutations and/or
acquisition of whole or parts of resistance genes. The commensal Neisseria spp. frequently
inhabit the human body and, consequently, are exposed more frequently to antimicrobials
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than the transiently acquired gonococcus. Thus, resistance may initially emerge in
commensal Neisseria spp., which act as a reservoir of AMR genes that can be readily
transferred to gonococci through transformation, particularly in pharyngeal gonorrhea
[1,17,34–36]. Pharyngeal gonorrhea is mostly asymptomatic, and gonococci and commensal
Neisseria spp. can coexist for extended time periods in the pharynx and share genetic
material. Once AMR determinants are acquired by N. gonorrhoeae, efficient intraspecies
transfer between gonococcal strains, via transformation, can spread these determinants
rapidly throughout the population. Horizontal gene transfer has likely played a pivotal role
in the spread of penA mosaic alleles, resulting in decreased susceptibility/resistance to ESCs
[23,25,37].
Acquired AMR determinants are stably maintained in the gonococcal population many
decades after withdrawal of the specific antimicrobials from treatment regimens [1,17,38].
This persistence and selection of AMR-resistant clones may be as a result of maintained
selective pressure in the community due to antimicrobials being used/misused to treat other
bacterial infections. However, the persistence may also be because the AMR determinants:
do not significantly affect biological fitness; lower the fitness, although this is compensated
by having a stabilizing second-site mutation(s); or even enhance the fitness and make the
AMR clones more successful in transmission and virulence [17,38]. For example, gonococci
lacking a functional MtrC–MtrD–MtrE multidrug-resistance efflux pump (a pump that
expels multiple antimicrobials and host-derived compounds from the cell) or MtrA (an
activator of mtrCDE transcription) had decreased fitness in murine competition experiments,
whereas gonococci lacking MtrR (a repressor of mtrCDE transcription) had increased fitness
compared with wild-type gonococci [39–41]. Interestingly, a spontaneous compensatory in-
host mutation in the mtrR locus of an mtrA mutant restored fitness to wild-type levels [40].
MtrR can regulate the expression of nearly 70 gonococcal genes and, accordingly, this
repressor may also be important for processes involved in basic metabolism, adaptation,
biological fitness and pathogenicity [42]. Similarly, gyrA91/95 mutations (encoding an
altered GyrA subunit of DNA gyrase), which cause decreased susceptibility/resistance to
ciprofloxacin, increased fitness compared with wild-type gonococci in the same murine
model. Inclusion of an additional parC86 mutation (encoding an altered ParC subunit of
topoisomerase IV), which further increases ciprofloxacin resistance, abrogated this fitness
advantage, but compensatory mutations could be isolated that restored in vivo fitness [43].
These examples demonstrate how AMR mechanisms can increase bacterial survival and
fitness, and suggest why AMR mechanisms are maintained despite discontinuation of
specific antimicrobials in treatment regimens. Thus, highly successful gonococcal clones
have acquired additional virulence determinants/enhanced biological fitness that allow them
to evade or render ineffective mucosal host defenses and spread widely to predominate in
local populations, with subsequent emergence in national and even international
populations. Attributes that determine success may or may not be affected by AMR
determinants [1,44], but when one of these successful clones acquires AMR determinants
for the antimicrobials used for treatment and is subsequently introduced to a high-frequency
transmitting population, resistance spreads quickly and widely, and these clones can
represent a large fraction of the gonococcal population [1,45,46].
Historically, most gonococcal AMR appears to have originated in the WHO Western Pacific
Region (WPR). For example, β-lactamase-mediated penicillin resistance, spectinomycin
resistance and fluoroquinolone resistance (with the latter being a well-documented
example), all appear to have originated and demonstrated high resistance prevalence in the
WHO WPR and subsequently spread worldwide, clearly illustrating that gonococcal AMR is
a global concern [1,17,23,25,47]. The first cases and/or outbreaks were identified in this
region and, particularly, resistance prevalence was high prior to mainly any resistance being
detected in other settings. These observations suggest that resistance emerged in the WHO
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WPR and, subsequently, spread via sex tourists, long-distance truck drivers and forced
migration, to the Pacific Rim countries within the WHO WPR, the USA, southeast and
central Asia, and Europe. To provide an evidence-basis for this hypothesis, it would be
valuable to model the emergence and spread of gonococcal AMR with an international
perspective; however, sufficient quality-assured geographical and temporal metadata
(regarding gonorrhoea patients, their sexual networks and the gonococcal population,
including its AMR and additional phenotypic and genetic characteristics) are lacking in most
settings worldwide. The reasons for emergence of AMR in the WHO WPR can only be
hypothesized, but likely factors include extensive use and particularly misuse of
antimicrobials in general, which results in AMR emergence in many bacterial species,
including N. gonorrhoeae, and in the treatment of gonorrhea itself. This misuse is catalyzed
by the unrestricted access to a huge variety of antimicrobials with consequent inappropriate
selection, overuse and, in some settings, the use of generic antimicrobials of suboptimal
quality and/or dose. This lack of optimal antimicrobial selection and use (in general and for
gonorrhea) is presumably due to deficient monitoring of AMR in vitro, clinical failures,
antimicrobial use and clinical efficacy of antimicrobials. Of particular concern, is that in
regions with a high incidence of gonorrhea and ineffective disease control measures to
decrease the gonorrhea burden, resistance can spread rapidly, nationally and internationally
[1].
Emergence and spread of in vitro & in vivo decreased susceptibility/resistance to ESCs
Over the past decade, strains of N. gonorrhoeae with decreased susceptibility/resistance to
ESCs appear to have emerged in Japan and spread internationally. In the 1990s through to
the early 2000s, ceftriaxone was not permitted for treatment of gonorrhea in Japan.
Therefore, a variety of oral ESCs, many comprising suboptimal efficacy, and dose regimens
were used in monotherapy (if resistance was indicated, cefodizime or spectinomycin was
used) [48,49]. Longer, multiple low-dose regimens of oral cephalosporins were commonly
utilized. Some of these regimens resulted in ESC concentrations that were subinhibitory,
which may thereby have selected for resistant clones [21,49–51]. In many settings
worldwide, only the most potent oral ESC, cefixime (in optimized 400 mg × 1 dose), has
been used for treatment. However, when applied, single dose cefixime therapy in Japan
included only 300 mg as a standard dose [52]. Thus, between 1995 and 2000, in Fukuoka,
Japan, the MIC peak of cefixime and ceftriaxone in gonococcal isolates increased from
0.008 μg/ml to 0.25 μg/ml, and from 0.015 μg/ml to 0.064 μg/ml, respectively [49].
Furthermore, in six hospitals in central Japan between 1999 and 2002, the proportion of
gonococcal isolates with decreased susceptibility/resistance to cefixime (MIC ≥0.5 μg/ml)
and ceftriaxone (MIC ≥0.5 μg/ml) increased, from 0 to 30.2% and from 0 to 0.9%,
respectively [50]. From 1999 to 2001, eight treatment failures with cefixime (200 mg orally
× 2; 6 h apart) were reported and isolates cultured from these patients had cefixime MICs of
0.125–0.25 μg/ml [21]. In 2002–2003, four treatment failures with an extended cefixime
regimen (200 mg orally twice a day for 3 days) were documented [30]. Isolates obtained
from these treatment failures exhibited substantially elevated MICs of cefixime (0.5–1 μg/
ml) and ceftriaxone (0.125–0.5 μg/ml). In 2006, all oral ESCs were excluded from treatment
guidelines in Japan.
The theory that gonococcal strains with decreased susceptibility/resistance to ESCs,
particularly oral ESCs, have spread internationally from Japan is in concordance with
decreased in vitro susceptibility to cefixime and ceftriaxone in WHO WPR countries,
including Australia, China, Hong Kong, Taiwan, USA, Canada, South America, southeast
Asia, the EEA and Russia, identified in subsequent years [1,3–20,23,25,32,33,45,47,51,53–
58,205]. For example, from 2009 to 2010, decreased susceptibility/resistance to cefixime in
EU/EEA gonococcal isolates increased from 4 to 9%, and this resistance phenotype was
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detected in 17 countries [203,205]. Worryingly, gonococcal AMR surveillance remains
sporadic, limited or even lacking in many regions worldwide, including Eastern Europe,
Central Asia, Africa, and large parts of South America and the Caribbean [1,12,20,59–61];
these regions also suffer from a high burden of gonorrhea [59,60,201]. Accordingly, the
global burden of decreased susceptibility/resistance to ESCs is unknown.
It is of concern that the first treatment failures with cefixime outside Japan [22,25–27] and
with ceftriaxone [23,24,28,29] have been verified in recent years. Furthermore, the first
three XDR [1] gonococcal isolates with high-level ceftriaxone resistance were recently
identified in Japan [23], France [25] and Spain [31].
Recently verified treatment failures with cefixime & ceftriaxone,
international spread of successful gonococcal strains & first strains with
high-level ceftriaxone resistance
Cefixime treatment failures
In 2010, the first verified cefixime treatment failures beyond Japan were reported in Norway
[27] and, subsequently, verified failures were documented in the UK [22], Austria [26] and
France [25]. The main characteristics of all microbiologically verified failures are described
in Table 1. Briefly, the cefixime MICs of the gonococcal isolates resulting in treatment
failure were 0.25–4 μg/ml and the country of infection varied widely. Nevertheless, all
genetically typed isolates belonged to either the multilocus sequence typing (MLST)
ST1901 and N. gonorrhoeae multiantigen sequence typing (NG-MAST) ST1407 or
genetically closely related NG-MAST STs, such as ST3779 and ST3431 (Table 1) [22,25–
27]. Disquietingly, the strain (referred to as F89) resulting in cefixime failure in a man who
has sex with men (MSM) in Quimper, France [25], appears to represent a subclone of the
MLST ST1901/NG-MAST ST1407 clone that has developed high-level resistance to
cefixime (MIC = 4 μg/ml) and ceftriaxone (MIC = 1–2 μg/ml). F89 was the second
identified XDR [1] gonococcal strain [25]. A genetically and phenotypically similar
ceftriaxone-resistant strain has subsequently been described in Spain, causing gonorrhea in
two MSMs with sexual contact [31]. This report illustrates that this ceftriaxone-resistant
strain can spread and, accordingly, does not have a deleteriously low biological fitness.
Ceftriaxone treatment failures
Five failures in treating pharyngeal gonorrhea with ceftriaxone, the last remaining treatment
option, have been verified in Australia (n = 2) [29], Sweden (n = 1) [24], Slovenia (n = 1)
[28], and Japan (n = 1) [23]. The Swedish [24] and Slovenian [28] treatment failures were
caused by the MLST ST1901/NG-MAST ST1407 clone. The main characteristics of these
failures are described in Table 2. The relatively low MICs of the gonococcal strains (with
exception of the one in Japan) causing these failures, especially those from Australia that
had near wild-type MICs (Table 2), likely reflecting the difficulty in treating pharyngeal
gonorrhea compared with urogenital infections [1,3,14,19,20,62–64]. Thus, it appears likely
that treatment failures with ceftriaxone will initially arise from pharyngeal gonorrhea.
Unfortunately, the failure to treat pharyngeal gonorrhea in a female sex worker with
ceftriaxone 1 g × 1 in Kyoto, Japan, was caused by the first ever XDR [1] N. gonorrhoeae
strain (‘H041’; the first gonococcal ‘superbug’), which displayed high-level resistance to
cefixime (MIC = 8 μg/ml) and ceftriaxone (MIC = 2–4 μg/ml), and to most other
antimicrobials tested (n = 28) [23]. Ceftriaxone treatment (1 g × 1) results in a median time
of free ceftriaxone above the MIC of only 6.0 h and 0 h for the detected MICs of 2 μg/ml
(agar dilution method) and 4 μg/ml (Etest®), respectively [51]. Consequently, even with this
treatment, H041 will escape eradication in almost any patient. H041 was assigned to MLST
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ST7363 and the novel NG-MAST ST4220 (Table 2). H041 may of accordingly represent a
subclone of the successful cefixime-resistant MLST ST7363, which has been prevalent in
Japan, that has also developed high-level ceftriaxone resistance [23,37,65].
International spread of successful gonococcal clones causing treatment failures with
ESCs
The gonococcal clones MLST ST1901 (commonly NG-MAST ST1407) and MLST ST7363,
both of which likely originated in Japan [23,25], were responsible for all of the verified
cefixime treatment failures and at least three of the five ceftriaxone treatment failures
(Tables 1 & 2); both of these clones are spreading worldwide [6,8,22,23,25–28,37,55,65–
73]. During the early 2000s, MLST ST1901 (frequently NG-MAST ST1407 in many
countries) started to replace MLST ST7363 as the most predominant MLST ST in Japan,
and it is currently responsible for most of the decreased susceptibility/resistance to ESCs in
Europe [6,8,23,25,65]. Nevertheless, although NG-MAST ST1407 is the most prevalent ST
of MLST ST1901 in Europe, many NG-MAST STs of this MLST clone have been identified
globally, particularly in Japan, where the MLST ST1901 clone has been spreading for many
years [6,8,22,25–28,65–72; 206].
Thus, two successful gonococcal clones (MLST ST7363 and MLST ST1901) are spreading
worldwide and both have demonstrated the capacity to develop high-level resistance to
cefixime and ceftriaxone, resulting in ESC treatment failures. Worryingly, the first three
strains with high-level ceftriaxone resistance were identified in high-risk, frequently
transmitting populations, such as H041 from a female sex worker in Japan [23], F89 in
France [25] and the Spanish strain from MSMs [31]. To date, further spread of H041 has not
been reported. However, F89 [25] and the genetically similar Spanish strain, transmitted
between two MSMs in Spain [31], may represent the first international transmission of N.
gonorrhoeae with high-level ceftriaxone resistance. If strains with high-level ceftriaxone
resistance spread globally, gonorrhea may become untreatable.
Verification of treatment failures
It is crucial to survey for and appropriately verify as well as follow-up treatment failures
with ESCs [1,202–204,207]. Recent WHO publications [1,202,207] have described in detail
important laboratory parameters to verify a treatment failure, which ideally requires
assessing pre- and post-treatment isolates for MICs, genotype, and genetic resistance
determinants. Additionally, a detailed clinical history that excludes reinfection and records
the treatment regimen used is mandatory. The correlates between genetic resistance
determinants, ESC MICs, and treatment outcome remain weak. It is crucial to examine all
gonococcal strains causing treatment failure as well as isolates showing high-level ESC
resistance in vitro, including determination of resistance determinants. This is essential to
establish appropriate MIC breakpoints for ESC resistance (together with pharmacokinetic/
pharmacodynamic simulations), to develop genetic methods for screening to identify
specific ESC-resistant clones and, ideally, to carry out genetic ESC resistance (and AMR in
general) testing.
Decreased susceptibility/resistance to ESCs: genetic resistance
determinants
Acquisition of resistance determinants from a resistant strain to a susceptible strain can be
achieved in the laboratory by step-wise transformation. Many studies have investigated the
steps of transformation for penicillin and ESC resistance, and these reveal a complex and
multifaceted interaction of at least four known resistance determinants (Figure 1): penA,
encoding altered forms of PBP2, the lethal target for β-lactam antibiotics; mtrR, resulting in
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overexpression of the MtrC–MtrD–MtrE efflux pump; penB, encoding mutations in the
major outer membrane porin; and ponA, encoding an altered form of PBP1. These and other
determinants are discussed in more detail below.
Alteration of PBP2, the lethal target for ESCs
The first step in decreased susceptibility/resistance to ESCs is alteration of the penA gene
encoding the transpeptidase PBP2 (Figure 2), the lethal target for ESCs and other β-lactam
antibiotics. Acquisition of penA mosaic alleles, and non-mosaic penA alleles with mutations
at A501, are associated with enhanced ESC MICs [8,23–28,31,36,37,52,68,69,71–87]. The
mosaic penA alleles appear to have evolved by DNA uptake and subsequent recombination
of partial penA genes from commensal Neisseria spp. commonly residing in the oropharynx
(i.e., Neisseria sicca, Neisseria perflava, Neisseria cinerea, Neisseria polysaccharea and/or
Neisseria flavescens) into the gonococcal penA gene [36,75,76,79]. Pharyngeal gonorrhea
may have provided the means for this in vivo intrageneric horizontal transfer [1,34–36]. The
relative increases in MICs due to acquisition of a penA mosaic allele appear to be higher for
cefixime than for ceftriaxone [23,25,86], which may be due to structure/activity
relationships associated with the longer side chain at the C-3 position of the cephem
skeleton of ceftriaxone [1,78–80,87].
Mosaic PBP2 variants contain up to 70 amino acid alterations compared with the wild-type
PBP2 [23]. Takahata et al. initially suggested that three of these alterations, G545S, I312M
and V316T, were responsible for the ESC resistance (by altering the β-lactam binding
pocket) [79], especially to cefixime [80]. However, it was subsequently shown that while
reversion of these three amino acids to wild-type dramatically decreased ESC resistance,
introduction of these same amino acids into the wild-type PBP2 sequence had little to no
effect on resistance. These data suggest that the three mutations only increase resistance in
the presence of other mutations in the penA mosaic alleles that have little or no apparent
effect on their own [81], a phenomenon known as epistasis. Inspection of the crystal
structure of PBP2 reveals that the G545S mutation is present at the beginning of the a11
helix, one of the two helices on top of the five anti-parallel β-strands typical of β-lactam-
interacting proteins. The main chain amides of G545 and G546 are within hydrogen-bonding
distance of the side chain hydroxyls of Thr498 and Thr500, respectively, located within the
KTG(T) active site motif (Figure 3a). The main chain amide of Thr500 is predicted to form
the oxyanion hole for stabilization of the transition state and, thus, one effect of the G545S
mutation might be to lower acylation by compromising the geometry of the transition state/
tetrahedral intermediate. Alternatively, the hydroxyl side chains of Thr498 and Thr500 may
interact with the β-lactam carboxylate in the covalent complex, and alteration of these
contacts may also lower the acylation [81]. Ile312 and Val316 are located on the opposite
side of Ser310 and Lys313 of the SxxK active site motif on the α2 helix and pack into a
hydrophobic pocket (Figure 3b). Mutation to larger (I312M) or more hydrophilic (V316T)
side chains might disrupt these interactions and alter the position of the SxxK active site
motif, which would also result in decreased acylation [81]. Tomberg et al. also verified that
an additional mutation, N512Y, contributes to decreased susceptibility/resistance to ESCs
(without affecting penicillin susceptibility), although it plays a lesser role than the three
alterations discussed above. N512 is relatively distant from the active site (Figure 3b) on the
β3–β4 loop, and it is possible that the N512Y alteration perturbs the architecture of the KTG
active site motif of the β3 strand [81].
Characterization of the novel penA mosaic allele in the first described XDR [1] strain,
H041, with high-level resistance to cefixime (MIC = 8 μg/ml) and ceftriaxone (MIC = 2–4
μg/ml), revealed 12 additional amino acid alterations compared with penA mosaic allele X,
which has been associated with cefixime treatment failures in Japan [23]. Transformation
experiments using full-length and partial penAH041 mosaic alleles indicated that the novel
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A311V and T316S alterations may contribute to high-level ESC resistance, due to the
proximity to the β-lactam active site in PBP2 (Figure 3b) [23]. However, the full cause of
ESC resistance in H041 needs to be appropriately elucidated, which is in progress.
A single amino acid alteration at position A501 (mostly A501V, but sometimes A501T) in
PBP2, which until recently was found mainly in non-mosaic penA alleles, is associated with
decreased susceptibility/resistance to ESCs, particularly ceftriaxone
[8,25,31,52,68,69,74,77,80,81,83–85]. The rarity of strains containing a penA mosaic allele
with an A501 mutation may suggest that these strains have a lower biological fitness
[25,81], although this has not been formally investigated. A501 alterations could be
gonococcal-specific, as they have not yet been reported in any other Neisseria species,
suggesting that they may have evolved and been selected in gonococci through spontaneous
mutation and selective pressure with ESCs instead of by transformation from another
species [8,25,81,85]. In support of this hypothesis, the isolation of a spontaneous A501V
mutation during transformation experiments with mosaic penA alleles has been reported
[80]. Given the concern that A501 mutations might emerge in mosaic penA alleles, Tomberg
et al. examined the effects of introducing an A501V mutation into a mosaic penA allele and
transforming it into both a penicillin-susceptible and a penicillin-resistant gonococcal strain.
Introduction of the A501V mutation increased the MIC of both cefixime and ceftriaxone by
two- to three-fold, while the penicillin MIC decreased [81]. As originally feared, a strain
containing a traditional penA mosaic allele with an A501 mutation was reported only a year
later [25]. This strain (F89), which contained a penA mosaic allele XXXIV with an
additional A501P alteration, was the second XDR [1] strain identified and displayed high-
level resistance to cefixime (MIC = 4 μg/ml) and ceftriaxone (MIC = 1–2 μg/ml).
Transformation experiments confirmed that this novel penA mosaic allele was responsible
for the high-level ESC resistance [25]. Isolates harboring the penA mosaic allele XXXIV,
which commonly belong to the successful MLST ST1901/NG-MAST ST1407 clone, have
been reported in many countries worldwide [25,28,55,67–69,71,73,74], and it is of major
concern that an A501P (or similar) alteration will emerge in additional strains containing the
penA mosaic allele XXXIV or other penA mosaic allele. It has been suggested that
replacement of the methyl side chain of Ala501, which is located on the β3–β4 loop close to
the KTG active site motif of PBP2, with the more bulky side chains of valine (A501V) or
threonine (A501T), inhibits the binding of cefixime and ceftriaxone to PBP2 by clashing
with their R1 substituents [25,81]. The change of Ala501 to a proline (A501P) introduces
secondary structure alterations that may result in even more dramatic changes, which is
consistent with the much higher MICs conferred by the A501P alteration than the A501V
and A501T alterations [25]. The crystal structure of PBP2 showing all amino acids currently
verified to be involved in enhancing the MICs of ESCs is illustrated in Figure 3.
Enhanced efflux & decreased influx of ESCs
Specific mutations in the promoter and/or coding sequence of mtrR, a transcriptional
repressor of the mtrCDE operon, markedly increase the expression of the MtrC– MtrD–
MtrE efflux pump (‘mtrR resistance determinant’) that enhances the efflux of ESCs,
particularly ceftriaxone, from the periplasmic space of the gonococcus and increases their
MICs. The mtrR determinant is most often a single-base-pair (A) deletion in the 13-base pair
(bp) inverted repeat of the promoter region, with G45D mutations (and other mutations)
within the coding sequence of MtrR being less common [8,23–28,31,36,39–
41,58,68,74,78,82,86,88–91]. Other rare alterations that increase expression of the MtrC–
MtrD–MtrE efflux pump have been described: a 153-bp insertion sequence located between
the mtrR/mtrC promoter and the mtrC gene [92], and a C-to-T transition 120 bp upstream of
the mtrC start codon (termed mtr120) that results in a consensus -10 element and a novel
promoter for mtrCDE transcription [93].
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mtrR mutations affect resistance in two ways: by directly increasing efflux of the ESC and
by activating the penB resistance determinant, which has a resistant phenotype only when a
mtrR mutation is present [86]. The penB resistance determinant encodes an altered porB1b
allele with mutations that alter amino acid G101 (e.g., G101K) or both G101 and A102 (e.g.,
G101D/A102D) in the putative loop 3 of the PorB1b outer membrane porin. Acquisition of
penB results in decreased influx of ESCs, particularly ceftriaxone, into the cell and increases
their MICs [8,23–28,31,36,58,68,74,78,82,86,89,94,95]. Synergy between the penA mosaic
allele, mtrR, and penB has been reported in isolates with decreased susceptibility/resistance
to ESCs, particularly ceftriaxone [23,25,86]. Interestingly, the great majority of cefixime
resistance appears to be conferred by the penA mosaic allele, with mtrR and penB having
only a minor effect on its MIC, whereas ceftriaxone resistance is nearly equally dependent
upon penA and mtrR/penB. This result suggests that either cefixime does not readily diffuse
into the periplasm through PorB or that such diffusion is not altered by the penB
determinant. These data also suggest that cefixime is not an effective substrate for the MtrC–
MtrD–MtrE efflux pump. The net charge of cefixime (-2) differs from the net charge of
penicillin (-1) and ceftriaxone (-1), which may affect the permeation properties of cefixime
[86].
Other current or possible future resistance determinants
Alterations in ponA (the ponA1 allele encoding PBP1 with an L421P mutation) and pilQ
(encoding loss-of-function mutations in the pore-forming secretin PilQ protein of the type
IV pili), both of which are involved in high-level penicillin resistance in strains containing
penA alterations, mtrR and penB, do not appear to alter the ESC MICs in clinical isolates
[8,86,96–98]. The ponA1 allele is present in most isolates with decreased susceptibility/
resistance to ESCs. However, this likely only reflects that these strains arose by transfer of
penA mosaic alleles into pre-existing chromosomally mediated penicillin-resistant strains,
which persist in high prevalence in the gonococcal population, despite the fact that penicillin
was withdrawn from gonorrhea treatment regimens decades ago [86]. An unusual aspect of
the ponA1 allele in penicillin resistance is that the introduction of ponA1 into a strain with
penA, mtrR and penB resistance determinants has no effect on resistance, while reversion of
ponA1 to wild-type in a penicillin-resistant strain decreases the MIC by twofold [96]. This
may indicate epistasis or the presence of ‘factor X’, which is described in more detail below.
pilQ2 (or any other pilQ loss-of-function mutation) has never been reported in clinical
isolates, probably because it compromises type IV pilus formation and, thus, pathogenic
potential [17,97,99]. Nevertheless, the effect(s) of ponA and/or pilQ polymorphisms in
future ESC-resistant strains cannot be totally excluded.
While penA, mtrR and penB determinants markedly increase resistance, they do not confer
donor levels of resistance to penicillin or ESCs (MICs ~three- to six-fold lower than donor
strains). Attempts by many labs to transform strains already containing penA, mtrR and
penB to donor MIC levels have been unsuccessful and, thus, the identity of this non-
transformable penicillin and ESC resistance determinant (termed ‘factor X’) remains
unknown [8,23,25,78,81,86].
Fortunately, acquisition or development of an extended-spectrum β-lactamase (ESBL),
which could degrade all ESCs, has not yet been reported in any gonococcal strain. However,
in many strains the blaTEM-1 gene (encoding TEM-1 β-lactamase) appears to have evolved
by one single nucleotide polymorphism (SNP) to blaTEM-135 and only one additional
specific SNP could result in an ESBL [100].
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Public health actions to meet the large challenge of emergence of high-
level ceftriaxone-resistant & untreatable gonorrhea
In the age of easy international travel, the global trend of AMR in gonococci and resistance
to ESCs, including treatment failures, demands a global approach to respond to the potential
public health disaster that may occur with the emergence of untreatable gonorrhea. This is
imperative, since gonococcal AMR data are lacking in many settings and the true global
problem is, therefore, unknown. Accordingly, the WHO Global Gonococcal Antimicrobial
Surveillance Programme (WHO Global GASP), initially established in the 1990s, was
revisited and revamped in 2009, in close liaison with other existing AMR surveillance
programs, in order to enable a coordinated global response. The WHO Global GASP
network aims to recruit laboratories worldwide to: monitor quality-assured gonococcal
AMR data (with particular attention to ESCs); provide support to establish gonococcal
culture and AMR testing; inform public health authorities and treatment guidelines on trends
in gonococcal AMR; optimize early detection of emerging resistance; and identify and
verify treatment failures with ESCs [33].
To facilitate the functioning of this WHO GASP network and engage the support of
governments, the international community and appropriate donors, the WHO recently
published the ‘Global action plan to control the spread and impact of AMR in Neisseria
gonorrhoeae’ [33,202]. This plan aims to enhance AMR surveillance worldwide through the
WHO Global GASP, facilitate early detection and verification of resistance to recommended
treatment (particularly ESCs) and combine these with a public health response to mitigate
the impact of ESC-resistant gonococci on sexual and reproductive health morbidity. The
WHO global action plan calls for a public health approach to the control of gonorrhea and
the emergence of untreatable gonorrhea. The main components of the WHO global action
plan are summarized in BOX 1. Several region-specific and national action/response plans to
mitigate the spread of multidrug-resistant gonorrhea, which are also crucial for the global
response, are under preparation or have been published. For example, the European CDC
and the US CDC have launched public health response plans for EU/EEA countries [203]
and the USA, respectively [204].
Future options for treatment & prevention of gonorrhea
Even if the aforementioned action/response plans will be fully implemented, they would
likely only delay, as opposed to halt, the inevitable international emergence and spread of
ceftriaxone-resistant gonorrhea. Ultimately, new treatment strategies and novel
antimicrobials are essential for the effective treatment of gonorrhea.
Increased doses of ESCs
Use of an increased dose of ceftriaxone has been implemented in most settings
[1,21,26,51,59,101,102]. In some countries, such as Japan and China, ceftriaxone 1 g × 1 is
recommended [59,101,103,104], and likely up to 2 g × 1 would be safe, based on the dosage
used for treatment of community-acquired pneumonia. Cefixime is not licensed for doses
higher than the currently used 400 mg × 1, due to frequent adverse gastrointestinal effects
observed with a higher dose (800 mg × 1) [105]. Even so, increased doses of ceftriaxone
will only provide a short-term solution. No currently available alternative cephalosporins,
either injectable or oral, offer any advantage over ceftriaxone or cefixime in terms of
efficacy and pharmokinetics/pharmacodynamics, and efficacy for pharyngeal infection is
even less certain [14,19,62,64].
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An alternative approach to increasing the dose in ESC monotherapy is to use dual
antimicrobial therapy, which also covers concurrent chlamydial infection, and recently this
has been introduced in the UK [64], the whole of Europe [Bignell C, Unemo M. European
guideline on the diagnosis and treatment of gonorrhoea in adults (2012), Submitted] and the
USA [19,106]. In the UK, ceftriaxone 500 mg × 1 (intramuscularly) plus azithromycin 1 g ×
1 (orally) have been recommended since 2011 for uncomplicated anogenital gonorrhea [64].
The recommendation in the USA is ceftriaxone 250 mg × 1 (intramuscularly) plus
azithromycin 1 g × 1 or doxycycline 100 mg (orally) twice-daily for 7 days [19,106].
Synergy has been reported for ESCs and azithromycin in treatment, including for pharyngeal
gonorrhea [107,108], and synergistic and/or additive effects can also be observed in vitro
[UNEMO M, UNPUBLISHED DATA]. Dual antimicrobial therapy might also inhibit future development of
gonococcal AMR. Accordingly, dual antimicrobial therapy appears effective, and, in fact,
has been practiced in several years, primarily due to the frequent co-administration of
azithromycin to gonorrhea patients for possible concomitant chlamydial infection.
Unfortunately, susceptibility to ceftriaxone is decreasing, resistance to doxycycline is
common and resistance to azithromycin has been selected rapidly in settings where it has
been frequently used. In recent years, isolates with high-level resistance to azithromycin
(MIC ≥256 μg/ml), due to an A2059G alteration (Escherichia coli numbering) in domain V
in three or four of the four alleles of the 23S rRNA gene, have also been identified in several
countries [109–113]. In the USA, a randomized clinical multicenter trial to evaluate the
efficacy (and safety) of gentamicin (240 mg × 1 intramuscularly) plus azithromycin (2 g × 1
orally) and gemifloxacin (320 mg × 1 orally) plus azithromycin (2 g × 1 orally) for treatment
of uncomplicated urogenital gonorrhea is also ongoing. In order to minimize the
gastrointestinal side effects when administering 2 g × 1 of azithromycin, it would be
valuable to have the new extended-release microsphere formulation of azithromycin
available worldwide. Nevertheless, dual antimicrobial regimens, especially those with
injections, might not be feasible and/or affordable in less-resourced settings, many of which
suffer from the highest gonorrhea burden.
Antimicrobial monotherapy: any future options?
Effective antimicrobial monotherapy, or at least new antimicrobials for inclusion in a dual
antimicrobial therapy regimens, appear essential for a long-term solution and from a global
perspective. The aminocyclitol spectinomycin (2 g × 1 intramuscularly) is a theoretical
option, and resistance to spectinomycin is also rare worldwide [1,3,7,14,18,23].
Unfortunately, high-level resistance to spectinomycin rapidly emerged when it was widely
used as a first-line option among US military personnel in Korea in the 1980s [114]. This
resistance was due to only one SNP, C1192T (E. coli numbering), in the 16S rRNA gene.
High-level resistance can also result from alterations in ribosomal proteins [UNEMO M, UNPUBLISHED
DATA]. Furthermore, spectinomycin is not effective for treatment of pharyngeal gonorrhea and
it is currently not available in many countries [1,3,11,14,23,115], making it a poor candidate
for first-line treatment. There are few promising candidates in sight for new (or rediscovery
of old) antimicrobials or other compounds for effective treatment of gonorrhea
[1,3,11,14,19,23,25].
Nevertheless, the aminoglycoside gentamicin is now being considered for treatment of
gonorrhea in several countries. Gentamicin (240 mg × 1 intramuscularly) has also been used
as first-line treatment in Malawi since 1993 without any reported emergence of in vitro
resistance [116,117], and the in vitro susceptibility in Europe appears high [118]. However,
global susceptibility data remain sparse, appropriate correlates between MICs of gentamicin
and treatment outcome are lacking (e.g., no microbiological resistance breakpoints exist), no
data for treatment of pharyngeal or anorectal gonorrhea exist and it is not clear whether
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appropriate pharmacokinetic/pharmacodynamic targets for treatment of all cases of
anogenital and pharyngeal gonorrhea can be reached. A recent meta-analysis also found that
treatment with a single dose of gentamicin resulted in a pooled cure rate of only 91.5% (95%
CI: 88.1–94.0%) [119], which is substantially lower than the current criteria of ≥95%
effectiveness for recommended treatment of gonorrhea. Furthermore, gentamicin has mainly
been used in Malawi in syndromic management administered together with doxycycline
and, thus, in a dual antimicrobial therapy regimen and not as a single antimicrobial therapy.
Valuable information regarding the efficacy and safety of gentamicin in dual antimicrobial
therapy of gonorrhea will soon be available from the ongoing clinical trial mentioned above.
The new fluoroketolide (antimicrobial class: macrolides), solithromycin (CEM-101), has
recently been demonstrated to have high in vitro activity against gonococci, including ESC-
and multidrug-resistant isolates [120]. Solithromycin had an activity that was fourfold
(MIC50) to 32-fold (MIC90) better than that of azithromycin and also appeared superior to
most other antimicrobials tested [120]. The three binding sites for solithromycin (compared
with two for other macrolides) on the bacterial ribosome probably result in this higher
activity and are also expected to delay resistance development [120,121]. Solithromycin is
well absorbed orally, with high plasma levels, intracellular concentrations and tissue
distribution, has a long post-antibiotic effect, and a 1.6 g × 1 oral dose appears well-tolerated
[122]. Accordingly, solithromycin might be appropriate for single antimicrobial therapy,
especially of infections by ESC-resistant strains, and particularly in dual antimicrobial
therapy of gonorrhea, which likely would further delay resistance development.
Furthermore, the susceptibility of Chlamydia trachomatis [123] and Mycoplasma genitalium
[124] to solithromycin indicates that it may be an option for treatment of several sexually
transmitted infections, including management of urethral and vaginal discharge syndromes.
Nevertheless, gonococcal isolates with ribosomal mutations resulting in high-level
resistance to azithromycin (MIC ≥256 μg/ml) have MICs of 4–32 μg/ml for solithromycin,
which presumably reflects resistance [120]. In the USA, a minor open-label, single-center
study to evaluate the efficacy and safety of an oral 1.2 g × 1 dose of solithromycin for
treatment of uncomplicated urogenital gonorrhea is ongoing.
The in vitro activity of ertapenem (parenteral 1-β-methyl-carbapenem) against N.
gonorrhoeae also appears to be high [125]. Ertapenem did not have any in vitro advantage
over ceftriaxone for isolates that were susceptible or intermediate-susceptible to ceftriaxone.
Nevertheless, for isolates with resistance to ceftriaxone (MIC = 0.5–4 μg/ml), the
corresponding MICs of ertapenem remained low (0.016–0.064 μg/ml) [125]. Ertapenem was
also highly active against multidrug-resistant isolates [125], as well as being safe, well-
tolerated and effective against urinary tract infections [126,127]. Thus, ertapenem might be a
treatment option for gonorrhea, particularly for the currently identified ESC-resistant cases
and especially in dual antimicrobial therapy. However, despite the observation that
ceftriaxone-resistant isolates (n = 4) had relatively low ertapenem MICs, ESC resistance
determinants, such as mosaic penA alleles, mtrR and penB, increase the MIC of ertapenem
[125]. The decrease in susceptibility to ertapenem indicates that gonococci have already
acquired initial determinants for ertapenem resistance, and the eventual remodeling of PBP2
to specifically exclude ertapenem, which would work synergistically with the existing
resistance determinants, seems likely. Due to these facts and the pharmacokinetic/
pharmacodynamic considerations of ertapenem, it may not be suitable for future gonorrhea
treatment. Finally, the future possibility of acquisition of a carbapenemase or a TEM-1 β-
lactamase that evolves into an ESBL to degrade ertapenem cannot be excluded, especially
when the blaTEM-1 gene appears to be evolving [100].
Tigecycline, a broad-spectrum parenteral glycylcycline, is a tetracycline derivative that has
shown high in vitro activity against gonococci, including tetracycline-resistant isolates
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[3,14,128]. However, tigecycline has not been examined against multidrug-resistant
gonococci (including ESC-resistant isolates) or evaluated in vivo for treatment of gonorrhea.
Furthermore, because tigecycline is mainly eliminated into the bile and a relatively small
proportion of the administered drug is excreted unchanged in the urine, the use of
tigecycline for treatment of urinary tract infections has been debated [129–131].
Evaluation of novel treatment options
All novel single or dual antimicrobial treatment regimens for gonorrhea ideally require up-
to-date and comprehensive in vitro and in vivo evaluation, including appropriately designed,
randomized and controlled treatment studies evaluating parameters such as efficacy, safety,
toxicity, cost, optimal dose and pharmacokinetic/pharmacodynamics data for genital and
extragenital (especially pharyngeal) gonorrhea. Furthermore, knowledge regarding current
and future genetic resistance determinants (in vitro selected and in vivo emerged) for these
antimicrobials (both in gonococci and bystander organisms when treating gonorrhea) clear
correlates between genetic and phenotypic laboratory parameters, and clinical treatment
outcomes, would be exceedingly valuable.
Pipeline for future therapeutic options
There are no novel antimicrobial options for the effective treatment of gonorrhea in late
development [1,11,14,17,19,23]. N. gonorrhoeae has rapidly developed resistance to all
antimicrobials introduced for first-line therapy during the last 70–80 years [1,11,17]. Given
the fear of emergence of untreatable gonorrhea, it is essential to think ‘outside the box’ and
investigate new targets, compounds and strategies for treatment, and, ideally, to develop an
effective gonococcal vaccine.
Pleuromutilin antimicrobials are potent inhibitors of bacterial protein synthesis that bind to
novel sites on bacterial ribosome, which are active against gonococci and suitable for
systemic use [132,133]. Both the pleuromutilins and novel inhibitors of bacterial
topoisomerases targeting regions different from the fluoroquinolone-binding site [134] may
deserve attention for potential antimicrobial treatment of gonorrhea.
Other novel compounds that are under development or could be developed include: species-
specific FabI inhibitors with activity against gonococci, such as MUT056399 [135];
inhibitors of efflux pumps that increase the susceptibility to certain antimicrobials, innate
host defense and toxic metabolites [136]; LpxC inhibitors having potent antigonococcal
activity [137]; molecules mimicking host defensins; and host defense peptides such as
LL-37 (multifunctional cathelicidin peptide) [138].
Prospects for a gonococcal vaccine
The search for a gonococcal vaccine is complicated, since even a natural uncomplicated
gonococcal infection results only in a mostly local, relatively low and non-persistent
immune response that provides little to no protection to reinfection even with an identical
strain. To date, no vaccine has been developed, despite the fact that whole organisms,
numerous purified gonococcal components and recombinant proteins have been tested. The
major obstacles for developing a vaccine have been: gonococcal production of non-
bactericidal antibodies (e.g., against Rmp) that block bactericidal antibodies (e.g., against
PorB and LOS); sialylation of gonococci and subsequent binding of alternative complement
regulator factor H; potential elicitation of gonococcal IL-17 responses that suppress Th1/Th2
adaptive immune responses to natural infection; high antigenic heterogeneity in gonococci
(including antigenic variability and phase variation of surface structures, e.g., pili, Opa
proteins and LOS); general lack of correlates for immune protection; and lack of an ideal
animal model for this obligate human pathogen [139–141]. Nevertheless, several recent
Unemo and Nicholas Page 13













advances may enable future gonococcal vaccine research: development of transgenic mouse
models expressing human genes required for gonococcal infection; better definition of the
course of natural infection through the use of experimental infection in male volunteers
[142]; enhanced knowledge regarding development of polyvalent vaccines (which might be
required for gonorrhea) gained from the reverse vaccinology technology used for
meningococcal vaccines [143]; modern molecular biology, including genome sequencing for
the identification of novel single or multiple vaccine candidate antigens; recombinant
protein vaccines; discoveries in genital mucosal immunology; and intranasal immunization
for increased local mucosal immune responses [140,141,144]. A vaccine that generates a
partial immunity, which might not inhibit uncomplicated gonorrhea but eradicates the severe
complications of the disease, would still be valuable.
Future perspective
It appears inevitable that ceftriaxone-resistant gonococcal strains with retained resistance
determinants to previously recommended antimicrobials will spread internationally, possibly
heralding an era of untreatable gonorrhea. This would be an exceedingly serious public
health problem that would result in substantial morbidity from the severe sequelae caused by
untreated gonorrhea worldwide.
Accordingly, timely, decisive, multidisciplinary and multicomponent public health actions
are essential worldwide. Strict implementation of the WHO global action plan [33,202] and
region-specific action/response plans [203,204] is crucial. The WHO Global GASP, in close
liaison with other regional/national GASPs, needs to: substantially enhance gonococcal
AMR surveillance worldwide, with a focus on ESCs; inform public health authorities about
national and regional treatment guidelines; optimize early detection of emerging AMR; and
support the early identification, verification and follow-up (including tracing of sexual
contacts) of treatment failures [33,202,207].
Currently, quality-assured surveillance of gonococcal AMR and treatment failures remains
sporadic, limited or lacking in many regions globally [1,12,20,59–61]. The limited use of
gonococcal culture and AMR testing worldwide is mostly the result of using syndromic
management and microscopy for diagnosis in less-resourced settings, and nucleic acid
amplification tests in more resourced settings. It is crucial to culture more isolates, examine
AMR, and identify specific ESC resistance determinants, to facilitate AMR surveillance and
develop sensitive and specific genetic ESC resistance testing assays. The recently revised
WHO standards [207] describe appropriate sampling, transportation and culture of
gonococcal isolates, quality-assured AMR testing using WHO gonococcal reference strains
[82] and methods to increase the sampling for AMR testing, such as using targeted culture
of N. gonorrhoeae microscopy and/or nucleic acid amplification test-positive samples.
Furthermore, well-established GASPs should increase the number and representativeness of
gonococcal isolates tested (most GASPs include mainly isolates from symptomatic male
urethritis from relatively few clinics per country) and epidemiological data collected to
prevent emergence of AMR in overlooked populations. Finally, it is also crucial to optimize
and, as much as feasible, harmonize the methods, interpretative criteria (breakpoints) and
internal and external quality assurance used globally. This is essential to be able to compare
validated and quality assured AMR data internationally.
The WHO global action plan [33,202] additionally stresses the importance of combining
enhanced surveillance of AMR and treatment failures with a public health response to
mitigate the emergence, spread and impact of gonorrhea, particularly ESC-resistant
gonococci. Accordingly, crucial actions also include: encouraging increased awareness of
gonococcal AMR; correct use of antimicrobials; effective early prevention (e.g.,
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information, counseling and safe sex), diagnosis and management of gonorrhea; effective
drug regulation and prescription policies (using only ideal antimicrobials of appropriate
quality and optimized doses); development of molecular methods for detecting and
monitoring ESC resistance; and, most importantly, research (basic science, in vitro and in
vivo studies) to identify new effective treatment strategies, novel antimicrobials and ideally
a vaccine (BOX 1) [1,33,202]. An increased focus on preventing, diagnosing and treating
pharyngeal gonorrhea, with special attention to pharmacokinetic/pharmacodynamic
considerations, is also crucial. This includes increasing the sampling of pharyngeal
specimens and promoting condom use when practicing oral sex. Pharyngeal infections are
harder to treat than urogenital infection, they are relatively common and represent an
asymptomatic reservoir for infection and emergence of resistance [1,3,14,17,19,20,34–
36,62–64]. Finally, widespread implementation of test-of-cure is important to identify
treatment failures and reinfection – particularly, but not only, for pharyngeal infections.
Genetic methods for detecting and monitoring ESC resistance would be extremely valuable,
and some methods identifying different or specific penA mosaic alleles or other
chromosomal AMR determinants have been developed [71,145–149]. Unfortunately, the
currently available penA mosaic PCR detection methods have suboptimal sensitivity and
specificity in their predictive power of ESC resistance, in general, and are suboptimal for
clinical specimens. The reasons for this are that the MICs of ESCs for strains with different
mosaic and Ala501-altered non-mosaic penA alleles vary markedly, making it crucial to
sequence the penA gene (rather than simply using some penA mosaic PCR that detects all
the different types of penA mosaic alleles or only a specific penA mosaic allele) and identify
other AMR determinants in these isolates. Additionally, most penA mosaic sequences
originate in commensal Neisseria species, making it hard to determine ESC resistance
particularly in extragenital specimen such as those taken from the pharynx
[1,8,23,25,72,77,80,83,84]. Initially, statistical associations between specific amino acid
alterations and elevated ESC MICs are exceedingly important to identify. However, this
approach also requires subsequent verification of the amino acid alterations (including their
possible epistasis) that enhance the MICs of ESCs by transformation of site-directed penA
mutants into isogenic strain backgrounds. It is also important to agree on the nomenclature
of gonococcal penA alleles (or PBP2 alleles), which includes generating an internationally
accessible database containing the full-length sequence, the name of the allele, and, ideally,
appropriate additional microbiological, genetic and epidemiologic data.
Nevertheless, accumulating knowledge regarding ESC resistance determinants combined
with recent advances in genome sequencing, nanotechnology and other molecular
approaches might enable sensitive and specific genetic ESC resistance assays (ideally at
point-of-care [POC]), as well as genetic POC diagnostic tests, which might substantially
improve early detection, particularly in less resourced settings worldwide. These POC tests
should be able to detect not only ESC resistance/susceptibility, but also resistance/
susceptibility to many of the antimicrobials previously recommended for treatment of
gonorrhea, and the results should be available in a timely manner and used not only for
gonococcal AMR surveillance, but also to direct the treatment of the individual patient.
Nevertheless, it is essential to retain culture and phenotypic AMR testing methods, that is, to
be able to detect novel resistance and inform the design and redesign of the genetic AMR
assays. New sequencing technologies can also substantially improve the molecular
epidemiological typing of gonococci [150], elucidate the dynamics of the national and
international spread of AMR gonococcal clones (microepidemiology and
microepidemiology), and detail the evolution of successful AMR gonococcal clones and
their AMR determinants, including prediction of emergence.
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Unfortunately, the aforementioned action/response plans will only delay and limit, but not
halt, the inevitable spread of ceftriaxone resistance globally. Therefore, it is essential to
develop novel treatment strategies and antimicrobials in a timely manner. Using an
increased dose of ceftriaxone will provide a short-term solution, but introduction of dual
antimicrobial therapy (currently ceftriaxone and azithromycin) covering concurrent
chlamydial infection [19,64,106], is recommended for most settings and, hopefully, will also
inhibit future development of gonococcal AMR. Additional research is needed regarding
which antimicrobials (and at what dosages) to combine, and to document efficacy, side
effects, pharmacokinetic/pharmacodynamic parameters, resistance development (in
gonococci and bystander organisms), in vitro methods for synergy testing and
microbiological resistance breakpoints. Unfortunately, gonococcal strains with decreased
susceptibility/resistance to ceftriaxone with concomitant resistance to both azithromycin and
doxycycline are already circulating globally, making it crucial to develop new alternatives
for dual antimicrobial therapy. Furthermore, dual antimicrobial therapy, especially with
injectable antimicrobials, might not be feasible and/or affordable in less-resourced settings
(with a substantial gonorrhea burden) and, thus, may not significantly mitigate AMR
emergence and global spread.
Accordingly, from a global perspective, an antimicrobial monotherapy appears essential
[1,17,23,25], however, currently there are no promising options [1,3,11,14,19,23,25].
Spectinomycin is a theoretical option, but it is not available in many countries and resistance
can be rapidly selected [1,3,14,114,115]. Nevertheless, it would be valuable to have
spectinomycin available to treat emergent ESC-resistant cases and possibly for inclusion in a
dual antimicrobial treatment regimen, which could inhibit the development of resistance and
effectively treat gonorrhoea, including pharyngeal infection. Although new antimicrobials
(i.e., gentamicin [116–119], solithromycin [120] and ertapenem [125]) have been suggested
for treatment, comprehensive and quality-assured in vitro and/or in vivo evaluation of these
antimicrobials remains lacking, and none appear ideal for single antimicrobial therapy. N.
gonorrhoeae has rapidly developed resistance to all antimicrobials introduced for first-line
therapy during the last 70–80 years [1,11,17] and, thus, it is essential to develop new
antimicrobials, investigate novel non-antimicrobial targets and define the mechanisms of
action for more sustainable treatment. A gonococcal vaccine would be especially useful,
however progress in this area remains minimal.
In conclusion, an era of untreatable gonorrhea may be approaching, which represents a
serious public health problem. It is crucial to implement action/response plans at global and
national levels, focus research and funding on enhanced surveillance of gonococcal AMR
(phenotypic and genetic) and treatment failures, and to improve the prevention, early
diagnosis and effective treatment of gonorrhea. Novel effective treatment strategies, new
antimicrobials (or other compounds) and, ideally, a gonococcal vaccine should be
developed.
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Box 1. Some of the main components and actions of the WHO global action
plan to control the spread and impact of antimicrobial resistance in
Neisseria gonorrhoeae
■ Advocacy for increased awareness on correct use of antibiotics among
healthcare providers and the consumers, particularly in key populations,
including men who have sex with men and sex workers
■ Effective prevention, diagnosis and control of gonorrhea, using prevention
messages, interventions, appropriate and recommended diagnosis and treat
ment regimens
■ Systematic monitoring, early detection and follow-up of treatment failures
with recommended treatment (cefixime and ceftriaxone) by developing a
standard case definition of treatment failure and protocols for verification,
reporting and management of failure
■ Effective drug regulations and prescription policies
■ Strengthened antimicrobial resistance surveillance, especially in countries
with a high burden of gonorrhea (and/or gonococcal antimicrobial
resistance), other sexually transmitted infections and HIV
■ Capacity building to establish regional networks of laboratories to perform
quality-assured gonococcal culture and antimicrobial susceptibility testing
■ Research to identify new molecular methods for detecting and monitoring
antimicrobial resistance
■ Research (basic science, in vitro and clinical studies) to identify alternative
effective strategies and/or novel antimicrobials (or other effective
compounds) for treatment of gonorrhea (and, ideally, a vaccine)
Data taken from [33,202].
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Public health concerns regarding gonorrhea & antimicrobial-resistant Neisseria
gonorrhoeae
■ Gonorrhea burden and multidrug-resistance in N. gonorrhoeae remain major
public health concerns that are poorly surveyed and controlled in global
terms.
Evolution, origin & spread of antimicrobial resistance in N. gonorrhoeae
■ Since the beginning of the antimicrobial era, N. gonorrhoeae has repeatedly
demonstrated an extraordinary capacity to develop resistance to all
antimicrobials introduced for treatment, mostly within only 1–2 decades.
■ The antimicrobial resistance determinants do not appear to significantly
decrease the biological fitness of the gonococci, with some even increasing
fitness, and are stably maintained in the gonococcal population decades after
withdrawal of the specific antimicrobials from treatment regimens.
Emergence & spread of in vitro & in vivo decreased susceptibility/resistance to extended-
spectrum cephalosporins
■ N. gonorrhoeae has now demonstrated its capacity to develop resistance to
the extended-spectrum cephalosporin ceftriaxone, the last remaining option
for first-line empiric monotherapy of gonorrhea, which has resulted in
treatment failures. An era of untreatable gonorrhea may be approaching,
which represents an exceedingly serious global public health problem.
Recent verified treatment failures with cefixime & ceftriaxone, international spread of
successful gonococcal strains & the first isolation of strains with high-level ceftriaxone
resistance
■ During recent years, cefixime treatment failures have been verified in many
countries, and the first confirmed clinical failures with ceftriaxone were
recently reported.
■ The gonococcal clones MLST ST1901 (commonly NG-MAST ST1407) and
MLST ST7363, both of which likely originated in Japan but have now spread
worldwide, have been responsible for most of these verified treatment
failures with cefixime and ceftriaxone. Both clones have also shown the
capacity to develop high-level resistance to ceftriaxone.
■ It is crucial to survey for and appropriately verify treatment failures with
cefixime and ceftriaxone.
Decreased susceptibility/resistance to extended-spectrum cephalosporins: genetic
resistance determinants
■ The mechanisms of resistance to extended-spectrum cephalosporins in N.
gonorrhoeae are complex and include diverse alterations in many genes such
as penA, mtrR and porB1b. It is crucial to elucidate the resistance
determinants in gonococcal isolates responsible for treatment failures with
extended-spectrum cephalosporins, as well as in isolates showing high in
vitro resistance. Rapid assays for genetic determination of resistance to
extended-spectrum cephalosporins would be exceedingly valuable for
resistance surveillance as well as clinical management of gonorrhea patients.
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Public health actions to meet the large challenge of emergence of high-level ceftriaxone-
resistant & untreatable gonorrhea
■ Essential actions to meet the large public health challenge of the possible
emergence of untreatable gonorrhea include implementing the WHO global
action plan and supporting regional/national response plans globally and
nationally; enhancing surveillance of gonococcal antimicrobial resistance,
treatment failures (including appropriate verification and follow-up of
failure) and antimicrobial use/misuse worldwide; and improving prevention,
early diagnosis and treatment to reduce the global burden of gonorrhea.
Future options for treatment & prevention of gonorrhea
■ There are few promising candidates in sight for new (or rediscovery of old)
antimicrobials or other compounds for effective treatment of gonorrhea.
■ Dual antimicrobial therapy (presently, ceftriaxone plus azithromycin) can be
recommended, particularly for settings suffering from decreased
susceptibility/resistance to extended-spectrum cephalosporins. However,
currently available antimicrobials (in current doses or in increased and/or
multiple doses) used alone or in combination may offer little prospect as
long-term solutions for effective gonorrhea treatment.
■ Novel effective antimicrobials (or other compounds) for treatment of
gonorrhea, and ideally a gonococcal vaccine must be developed.
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Figure 1. An illustration of the known resistance determinants responsible for decreased
susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae
penA encodes altered forms of PBP2, the lethal target for β-lactam antimicrobials. The
purple spheres indicate amino acid alterations in a mosaic PBP2 compared with wild-type
PBP2. Expression of mtrR results in overexpression of the MtrC–MtrD–MtrE efflux pump
and activation of penB. penB encodes mutations in the major outer membrane porin
(PorB1b) that decrease influx of antimicrobials. ponA, encoding an altered form of PBP1,
has been demonstrated to be involved in penicillin resistance, but not yet in resistance to
extended-spectrum cephalosporins. The structure of PBP2 is from Neisseria gonorrhoeae.
The other structures are from closely related structures in other bacteria, that is, the MtrCDE
are of AcrAB-TolC from Escherichia coli; the structure of PorB1b is of Neisseria
meningitidis PorB and the structure of PBP1 is of E. coli PBP1b. The PDB codes are: 2f1M
(AcrA), 1IWG (AcrB), 1EK9 (TolC), 3A2R (PorB), 3FWM (PBP1) and 3EQU (PBP2).
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Figure 2. The structure of PBP2 from Neisseria gonorrhoeae
The C-terminal domain (transpeptidase domain) with the active site for binding of β-lactam
antimicrobials is at the top and the N-terminal domain (structural domain) that anchors
PBP2 to the cytoplasmic membrane at the bottom. The structure is color-ramped blue-to-red
in the N-terminal to C-terminal direction.
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Figure 3. Crystal structure of PBP2 displaying all amino acids currently verified to be involved
in enhancing the MICs of extended-spectrum cephalosporins
(A) Location of the G545S mutation and the β-lactam active site sequence motifs at the
crystal structure of PBP2. The interactions of Thr498 and Thr500 within the KTG(T) active
site motif with the main chain amides of Gly545 and Gly546 are illustrated. Mutation of
Gly545 to Ser incorporates a hydroxylated side chain that potentially could perturb the
interactions between the two Thr residues on β3 and the main chain of the α11 helix [81].
The SxxK active site motif is also shown. (B) The crystal structure of PBP2 showing the
location of all amino acid alterations (with the exception of G545S shown in A) currently
verified to increase the MICs of extended-spectrum cephalosporins. Ile312 and Val316 are
located on the opposite side of Ser310 and Lys313 of the SxxK active site motif on the α2
helix and pack into a hydrophobic pocket. Mutation to larger (I312M) or more hydrophilic
(V316T) side chains might disrupt these interactions and alter the position of the SxxK
active site motif. N512 is relatively distant from the active site on the β3–β4 loop and it is
possible that the N512Y alteration perturbs the architecture of the KTG active site motif of
the β3 strand [81]. Replacement of the methyl side chain of A501, which is located on the
β3–β4 loop close to the KTG active site motif, with the more bulky side chains of valine
(A501V), threonine (A501T) or proline (A501P) might inhibit the binding of extended-
spectrum cephalosporins by clashing with their R1 substituents [25,81]. The novel A311V
and T316S alterations, which are in close proximity to the β-lactam active site, appear to
contribute to high-level resistance to extended-spectrum cephalosporins [23]. Elucidation of
their effects in detail is in progress. Images were created in PyMol and were adapted from
[81].
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